HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Neutral 53.4%

Neg 0% Neu 53.4% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $50.